Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.48 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 8/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.56 |
| ▸ | USP2 | O75604 | 3/20 | 0.51 |
| ▸ | APAF1 | O14727 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.51 |
| ▸ | MC4R | P32245 | 2/20 | 0.51 |
| ▸ | UBE2N | P61088 | 2/20 | 0.51 |
| ▸ | RAD52 | P43351 | 2/20 | 0.51 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3939116 | 0.98 | ALDH1A1 (0.65) | ALDH1A1MEN1KMT2AUSP2APAF1 | |
| Iodide SCHEMBL1774982 | 0.89 | MEN1 (0.57) | ALDH1A1MEN1KMT2AUSP2APAF1 | |
| Iodide SCHEMBL1774984 | 0.89 | MEN1 (0.57) | ALDH1A1MEN1KMT2AUSP2APAF1 | |
| Iodide SCHEMBL29394388 | 0.88 | MEN1 (0.76) | ALDH1A1MEN1KMT2AUSP2APAF1 | |
| Iodide SCHEMBL22588126 | 0.88 | MEN1 (0.76) | ALDH1A1MEN1KMT2AUSP2APAF1 | |
| SCHEMBL4469449 | 0.87 | MEN1 (0.58) | ALDH1A1MEN1KMT2AUSP2APAF1 | |
| SCHEMBL4469450 | 0.87 | MEN1 (0.58) | ALDH1A1MEN1KMT2AUSP2APAF1 | |
| SCHEMBL8185372 | 0.79 | SIGMAR1 (0.50) | ALDH1A1MEN1KMT2AUSP2APAF1 | |
| Iodide SCHEMBL1777006 | 0.78 | MEN1 (0.46) | ALDH1A1MEN1KMT2AUSP2APAF1 | |
| Iodide SCHEMBL1775221 | 0.77 | MEN1 (0.60) | ALDH1A1MEN1KMT2AUSP2APAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943606-B2 | Compositions and methods to control abnormal cell growth | CANCURE LABORATORIES, LLC (US) | 2011-05-17 | — | — | US | claimed |
| US-20100215635-A1 | SMALL MOLECULES TO INDUCE WEIGHT LOSS OR TO REDUCE WEIGHT GAIN | KISS ZOLTAN | 2010-08-26 | — | — | US | claimed |
| US-20100048668-A1 | COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH | CANCURE LABORATORIES, LLC (US) | 2010-02-25 | — | — | US | claimed |
| US-20100022617-A1 | COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH | CANCURE LABORATORIES, LLC (US) | 2010-01-28 | — | — | US | claimed |
| US-20090317372-A1 | SMALL MOLECULES FOR THE REDUCTION OF HIGH BLOOD GLUCOSE LEVEL | KISS ZOLTAN | 2009-12-24 | — | — | US | claimed |
| US-20090030066-A1 | SMALL MOLECULES FOR THE PROTECTION OF PANCREATIC CELLS | ZOLTAN LABORATORIES LLC (US) | 2009-01-29 | — | — | US | claimed |
| EP-1931332-A2 | COMPOUNDS AND COMPOSITIONS TO CONTROL ABNORMAL CELL GROWTH | ZOLTAN LABORATORIES LLC (US) | 2008-06-18 | — | — | EP | claimed |
| WO-2007032818-A2 | COMPOUNDS AND COMPOSITIONS TO CONTROL ABNORMAL CELL GROWTH | ZOLTAN LABORATORIES LLC (US) | 2007-03-22 | — | — | WO | claimed |
| US-20070060634-A1 | COMPOUNDS AND COMPOSITIONS TO CONTROL ABNORMAL CELL GROWTH | ZOLTAN LABORATORIES LLC (US) | 2007-03-15 | — | — | US | claimed |
| US-7943606-B2 | Compositions and methods to control abnormal cell growth | CANCURE LABORATORIES, LLC (US) | 2011-05-17 | — | — | US | disclosed |
| US-20100215635-A1 | SMALL MOLECULES TO INDUCE WEIGHT LOSS OR TO REDUCE WEIGHT GAIN | KISS ZOLTAN | 2010-08-26 | — | — | US | disclosed |
| US-7781423-B2 | Compounds to promote regeneration of bone marrow | CANCURE LABORATORIES, LLC (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100048668-A1 | COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH | CANCURE LABORATORIES, LLC (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100022617-A1 | COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH | CANCURE LABORATORIES, LLC (US) | 2010-01-28 | — | — | US | disclosed |
| US-7423029-B1 | from endogenous or exogenous stem/progenitor cells and to normalize blood cell and platelet counts; e.g. [3-(3,4-dimethyl-9-oxo-9H-thioxanthen-2-yloxy)-2-hydroxypropyl]trimethylammonium chloride; antitumor and AIDS agent; low toxicity, side effect reduction | ZOLTAN LABORATORIES, LLC (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080207738-A1 | DRUG COMBINATIONS TO TREAT DRUG RESISTANT TUMORS | CANCURE LABORATORIES, LLC (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1931332-A2 | COMPOUNDS AND COMPOSITIONS TO CONTROL ABNORMAL CELL GROWTH | ZOLTAN LABORATORIES LLC (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20080114055-A1 | Thioxanthone Compounds to Reverse Weight Loss | ZOLTAN LABORATORIES LLC (US) | 2008-05-15 | — | — | US | disclosed |
| WO-2007032818-A2 | COMPOUNDS AND COMPOSITIONS TO CONTROL ABNORMAL CELL GROWTH | ZOLTAN LABORATORIES LLC (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060634-A1 | COMPOUNDS AND COMPOSITIONS TO CONTROL ABNORMAL CELL GROWTH | ZOLTAN LABORATORIES LLC (US) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090317372-A1 | SMALL MOLECULES FOR THE REDUCTION OF HIGH BLOOD GLUCOSE LEVEL | KCNN1, KCNN3, SLC2A9 | CHRM1 2728/4885CHRM3 2544/4885ALDH1A1 3664/4885 |
| US-20080114055-A1 | Thioxanthone Compounds to Reverse Weight Loss | TET1, TCOF1, CPT1B | CHRM1 165/4885CHRM3 432/4885ALDH1A1 1540/4885 |
| US-20080207738-A1 | DRUG COMBINATIONS TO TREAT DRUG RESISTANT TUMORS | ABCC1, BRCA1, VHL | CHRM1 4838/4885CHRM3 4861/4885ALDH1A1 2312/4885 |
| US-20100215635-A1 | SMALL MOLECULES TO INDUCE WEIGHT LOSS OR TO REDUCE WEIGHT GAIN | GPR119, FABP4, PNLIP | CHRM1 3155/4885CHRM3 2156/4885ALDH1A1 1372/4885 |
| US-20070060634-A1 | COMPOUNDS AND COMPOSITIONS TO CONTROL ABNORMAL CELL GROWTH | ALPP, DNTT, ALPG | CHRM1 4779/4885CHRM3 4395/4885ALDH1A1 2158/4885 |
| US-20100048668-A1 | COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH | ALPP, ALPG, MKI67 | CHRM1 4720/4885CHRM3 4519/4885ALDH1A1 1909/4885 |
| US-20090030066-A1 | SMALL MOLECULES FOR THE PROTECTION OF PANCREATIC CELLS | RNASE1, IAPP, POT1 | CHRM1 2499/4885CHRM3 1967/4885ALDH1A1 1155/4885 |
| US-20100022617-A1 | COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH | ALPP, ALPG, DNTT | CHRM1 4758/4885CHRM3 4283/4885ALDH1A1 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.